Description

CJC-1295 + Ipamorelin – 5mg / 5mg

CJC-1295 is a synthetic analog of Growth Hormone Releasing Hormone (GHRH), while Ipamorelin is a selective Growth Hormone Secretagogue (GHS) that targets the ghrelin receptor (GHS-R1a). When combined, these peptides are studied for their synergistic activation of endogenous growth hormone signaling pathways in laboratory models.

This dual-peptide formulation is engineered strictly for laboratory investigation into growth hormone pulsatility, IGF-1 modulation, recovery pathway signaling, and endocrine feedback regulation.

Purity: >99% (HPLC Tested)
Format: Lyophilized White Powder
Molecular Formula:
CJC-1295: C152H252N44O42
Ipamorelin: C38H49N9O5
Research Target: Growth Hormone Axis & IGF-1 Signaling Pathways

CJC-1295 binds to GHRH receptors to stimulate physiologic GH release in experimental models. Ipamorelin selectively activates ghrelin receptors, promoting GH secretion while demonstrating minimal observed interaction with ACTH, cortisol, or prolactin pathways compared to earlier secretagogues. The combination is studied for maintaining pulsatile GH release patterns while preserving regulatory endocrine feedback loops.

Research Observed Outcomes

Data from endocrine and metabolic research programs highlight the following findings in controlled laboratory environments:

Enhanced GH Pulse Amplitude and Frequency:
Combination studies demonstrate increased pulsatile GH release compared to single-agent stimulation.

IGF-1 Elevation in Experimental Models:
Sustained activation of the GH axis has been associated with increased circulating IGF-1 markers.

Sleep Architecture Research:
Ghrelin receptor activation has been linked to enhanced slow-wave sleep markers in laboratory sleep studies.

Lean Tissue Signaling Investigation:
Research indicates activation of anabolic signaling cascades including PI3K/AKT pathways.

Selective Endocrine Activation:
Ipamorelin demonstrates targeted GH stimulation with minimal activation of stress hormone pathways in controlled models.

Key Linked Studies & Research References

CJC-1295 Pharmacodynamics:
Teichman, S.L., et al. (2006). Prolonged stimulation of growth hormone secretion by CJC-1295. Journal of Clinical Endocrinology & Metabolism.

Ipamorelin Selectivity Research:
Smith, R.G., et al. (1999). Ipamorelin: a selective growth hormone secretagogue. Endocrinology.

Growth Hormone Axis Review:
Bowers, C.Y. (2001). Growth hormone-releasing peptides and analogs. Endocrine Reviews.

Sleep and GH Interaction:
Van Cauter, E., et al. (2000). Growth hormone secretion during sleep. Journal of Clinical Investigation.

Storage & Stability Protocols

To preserve peptide structure and receptor-binding stability:

Lyophilized Powder:
Store at -20°C for long-term stability. Stable at room temperature for short-term transit.

Reconstituted Stability (Bacteriostatic Water):
When reconstituted under sterile laboratory conditions, stability is typically maintained for 4–6 weeks under refrigeration (2°C – 8°C).

Reconstituted Stability (Sterile Water):
Stability is significantly shorter, typically 7–12 days due to absence of antimicrobial preservatives.

Handling:
Avoid repeated freeze-thaw cycles. Protect from excessive heat and light. Do not vigorously agitate during reconstitution.

⚠️ STRICT COMPLIANCE NOTICE: FOR LABORATORY RESEARCH ONLY
This product is a chemical research compound intended strictly for in vitro or laboratory experimentation. Any form of ingestion, injection, or topical application to humans or animals is STRICTLY PROHIBITED. This product is not a drug, food, or cosmetic and has not been approved by the FDA for any medical application. Handling must be performed by qualified professionals in controlled laboratory environments.